Study reveals racial disparities in prostate cancer care

August 23, 2012, Vanderbilt University Medical Center

A study led by investigators from Vanderbilt-Ingram Cancer Center (VICC), Nashville, Tenn., finds that black men with prostate cancer receive lower quality surgical care than white men. The racial differences persist even when controlling for factors such as the year of surgery, age, comorbidities and insurance status.

Daniel Barocas, M.D., MPH, assistant professor of Urologic Surgery, is first author of the study published in the Aug. 17 issue of the Journal of Urology.

Investigators from VICC, the Tennessee Valley Veterans Administration Geriatric Research, Education and Clinical Center, Nashville, and the Center for Quality Improvement and Patient Safety, Agency for Healthcare Research and Quality, Rockville, Md., were involved in the study of .

The researchers analyzed records of 105,972 patients who received radical prostatectomies in all nonfederal hospitals in Florida, Maryland and New York state from 1996 to 2007. Of the patients, 81,112 (76.5 percent) were white, 14,006 (13.2 percent) were black, 6,999 (6.6 percent) were Hispanic and 3,855 (3.6 percent) represented all other races.

Previous studies have found that men who are treated at high volume hospitals (HVH) by surgeons who do a high volume of prostatectomies (HVS) have better outcomes and lower mortality.

In this study, had 33 percent lower odds of using a high volume surgeon and 27 percent lower odds of visiting a high volume hospital than . Furthermore, black men had a higher rate of and longer length of stay in the hospital. They also were more likely to die in the hospital.

Black men who used HVH and HVS were at substantially decreased risk for adverse outcomes, including death, than those using lower volume health care providers, but still had worse outcomes than their white counterparts.

"Our findings of racial variation in the quality of surgical care for prostate cancer adds to previous studies that have shown in screening behavior, stage at presentation and use of aggressive treatment, and may contribute to our understanding of why black men have much higher prostate cancer mortality than white men," said Barocas.

The results suggest that black men may have more difficulty gaining access to high quality care.

"Racial disparities in prostate cancer outcomes may be partially explained by differences in access to high quality care, which in turn may reflect differences in patient resources," explained Barocas. "To close this gap, we may need interventions aimed at improving access to high quality care for all men, including access to high volume health care providers."

Related Stories

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.